RT Journal Article
T1 Comparative analysis of the immunomodulatory capacities of human bone marrow– and adipose tissue–derived mesenchymal stromal cells from the same donor
A1 Valencia Mahón, Jaris
A1 Blanco, Belén
A1 Yáñez, Rosa
A1 Vázquez García, Miriam Nohemi
A1 Herrero Sánchez, Carmen
A1 Fernández García, María
A1 Rodríguez Serrano, Concepción
A1 Pescador, David
A1 Blanco, Juan F.
A1 Hernando Rodríguez, Miriam
A1 Sánchez Guijo, Fermín
A1 Lamana, María Luisa
A1 Segovia, José Carlos
A1 Vicente, Ángeles
A1 Cañizo, Consuelo del
A1 Zapata González, Agustín Gregorio
AB Background aimsThe immunomodulatory properties of mesenchymal stromal cells (MSCs), together with their tissue regenerative potential, make them interesting candidates for clinical application.MethodsIn the current study, we analyzed the in vitro immunomodulatory effects of MSCs derived from bone marrow (BM-MSCs) and from adipose tissue (AT-MSCs) obtained from the same donor on both innate and acquired immunity cells. BM-MSCs and AT-MSCs were expanded to fourth or fifth passage and co-cultured with T cells, monocytes or natural killer (NK) cells isolated from human peripheral blood and stimulated in vitro. The possible differing impact of MSCs obtained from distinct sources on phenotype, cell proliferation and differentiation, cytokine production and function of these immune cells was comparatively analyzed.ResultsBM-MSCs and AT-MSCs induced a similar decrease in NK-cell proliferation, cytokine secretion and expression of both activating receptors and cytotoxic molecules. However, only BM-MSCs significantly reduced NK-cell cytotoxic activity, although both MSC populations showed the same susceptibility to NK-cell-mediated lysis. AT-MSCs were more potent in inhibiting dendritic-cell (DC) differentiation than BM-MSC, but both MSC populations similarly reduced the ability of DCs to induce CD4+ T-cell proliferation and cytokine production. BM-MSCs and AT-MSCs induced a similar decrease in T-cell proliferation and production of inflammatory cytokines after activation.ConclusionsAT-MSCs and BM-MSCs from the same donor had similar immunomodulatory capacity on both innate and acquired immunity cells. Thus, other variables, such as accessibility of samples or the frequency of MSCs in the tissue should be considered to select the source of MSC for cell therapy.
PB Taylor & Francis
SN 1465-3249
YR 2016
FD 2016-10
LK https://hdl.handle.net/20.500.14352/18331
UL https://hdl.handle.net/20.500.14352/18331
LA eng
NO Ministerio de Economía, Comercio y Empresa (España)
NO Comunidad de Madrid
NO Instituto de Salud Carlos III
NO Fundación Científica Asociación Española Contra el Cáncer
DS Docta Complutense
RD 8 abr 2025